Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials

Koushik Paul, Niranjan Sathianathen, Philipp Dahm, Chap Le, Badrinath R. Konety

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited.

Original languageEnglish (US)
Pages (from-to)385-390
Number of pages6
JournalJournal of Urology
Volume202
Issue number2
DOIs
StatePublished - Aug 1 2019

Bibliographical note

Funding Information:
Supported by the CHAAMPS (Center for Healthy African American Men through Partnerships), NIH (National Institutes of Health) Grant No. U54MD008620, the PHDR (Program in Health Disparities Research) at University of Minnesota Medical School and the MCC (Masonic Cancer Center) at University of Minnesota.

Publisher Copyright:
© 2019 American Urological Association Education and Research, Inc. Unauthorized.

Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.

Keywords

  • African Americans
  • clinical trial protocols as topic
  • registries
  • research design
  • urogenital neoplasms

Fingerprint Dive into the research topics of 'Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials'. Together they form a unique fingerprint.

Cite this